1493-54-5

Usage

Uses

Used in Organic Synthesis:
N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide is utilized as a reagent in organic synthesis for its ability to participate in a variety of chemical reactions, facilitating the creation of new compounds and structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide is employed as a key intermediate in the development of new drugs, leveraging its unique structural features to enhance the properties of medicinal compounds.
Used in Material Science:
N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide also finds application in material science, where its structural attributes contribute to the advancement of new materials with specific properties tailored for various applications.
Each of these uses underscores the versatility and importance of N-(9H-fluoren-9-yl)-2,2,2-trifluoro-acetamide in the fields of chemistry and research, highlighting its potential to drive innovation and contribute to the development of new technologies and therapies.

InChI:InChI=1/C15H10F3NO/c16-15(17,18)14(20)19-13-11-7-3-1-5-9(11)10-6-2-4-8-12(10)13/h1-8,13H,(H,19,20)

Upstream product

• 525-03-1 9-aminofluorene 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 38359-28-3 N-methyl-9H-fluoren-9-amine 

Relevant academic research and scientific papers

Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: Discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range

On the basis of the results obtained in previous research, three series of compounds (A-C), derived from verapamil, were designed and synthesized to obtain drugs able to revert multidrug resistance (MDR), an acquired resistance that frequently impairs cancer chemotherapy. The ability of the obtained compounds to revert MDR was evaluated on anthracycline-resistant erythroleukemia K 562 cells, measuring the uptake of THP-adriamycin (pirarubicin) by continuous spectrofluorometric monitoring of the decrease of the fluorescence signal of the anthracycline at 590 nm (λ(ex) = 480 nm), after incubation with cells. Cardiovascular activity, which is responsible for unwanted side effects, was also evaluated. The results obtained show that many of the compounds studied are potent reverters of MDR and are endowed with reduced cardiovascular activity. One of the compounds (7, MM36) presents a pharmacological profile (unprecedented nanomolar potency, high reversal of MDR, low cardiovascular activity) that makes it a promising drug candidate to treat MDR and a useful tool for studying P-glycoprotein.

Oxygen Sensitization of Electron Capture Response to Isomers of Polycyclic Aromatic Amines and Hydroxides

The use of the oxygen-sensitized constant-current electron capture detector (ECD) with gas chromatography for analyte identification is extended by examining the responses of numerous polycyclic aromatic amines and hydroxides where an appropriate EC-enhancing chemical tag has been attached to the amino group or the hydroxy group has been methylated.For the majority of isomeric groups examined, measured response enhancements of the derivatives are sufficiently dependent on structural differences as to provide an additional means by which substitution isomers can be differentiated.The ion chemistry responsible for the EC and oxygen-sensitized responses also has been examined by the use of an atmospheric pressure ionization mass spectrometer (APIMS).